Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Ghayathri Jeyakumar; Seongho Kim; Naresh Bumma; Craig Landry; Cynthia Silski; Stacey Suisham; Brenda Dickow; Elisabeth Heath; Joseph Fontana; Ulka Vaishampayan

doi:10.1186/s40425-017-0287-5

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

XML

Research Article

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Jeyakumar G, Kim S, Bumma N, et al

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Journal for ImmunoTherapy of Cancer 2017;5:82. doi: 10.1186/s40425-017-0287-5

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password